NASDAQ:NAMSW NewAmsterdam Pharma (NAMSW) Stock Price, News & Analysis $9.30 -0.19 (-2.00%) Closing price 11/16/2026 03:59 AM EasternExtended Trading$9.30 0.00 (0.00%) As of 11/16/2026 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsOwnershipSEC Filings About NewAmsterdam Pharma Stock (NASDAQ:NAMSW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$9.49▼$9.4950-Day Range$8.38▼$14.4952-Week Range$7.31▼$30.45VolumeN/AAverage Volume2,138 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing oral medicines for people with cardiovascular and metabolic diseases. Its research centers on treatments to lower LDL cholesterol and address cardiovascular risk, particularly for patients who need additional options alongside existing therapies. The company’s lead candidate, obicetrapib, is an investigational oral cholesterol-lowering medicine that inhibits CETP, a protein involved in lipid metabolism. NewAmsterdam has also studied obicetrapib in combination with ezetimibe. These treatments are under development and are not described here as approved or commercially available products. NewAmsterdam Pharma is based in Naarden, the Netherlands. Michael Davidson, a physician and lipid specialist, has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Receive NAMSW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMSW Stock News HeadlinesThe Billionaire-Backed Pharma Play Sitting on a $640M Cash Pile at 52-Week LowsNovember 7, 2026 | insidermonkey.comNewAmsterdam Pharma Begins Phase 2b Preclinical Alzheimer’s TrialSeptember 29, 2026 | tipranks.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 17 at 1:00 AM | Base Camp Trading (Ad)EU Approval of Obicetrapib Products Strengthens NewAmsterdamSeptember 21, 2026 | tipranks.comAnalyst Reiterates Buy on NewAmsterdam Pharma as PREVAIL Study Changes and Interim Analysis Boost Confidence in Obicetrapib’s Cardiovascular OutcomesSeptember 18, 2026 | tipranks.comNewAmsterdam Pharma: Potential Coupled With UncertaintySeptember 8, 2026 | seekingalpha.comNewAmsterdam Pharma Appoints New Principal Accounting OfficerAugust 14, 2026 | tipranks.comNewAmsterdam Pharma reports $3.7 million second quarter revenueAugust 5, 2026 | quiverquant.comQSee More Headlines NAMSW Stock Analysis - Frequently Asked Questions How have NAMSW shares performed this year? NewAmsterdam Pharma's stock was trading at $22.99 at the beginning of 2026. Since then, NAMSW stock has decreased by 59.5% and is now trading at $9.30. Who are NewAmsterdam Pharma's major shareholders? Top institutional shareholders of NewAmsterdam Pharma include RA Capital Management L.P.. How do I buy shares of NewAmsterdam Pharma? Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NAMSW's financial health is in the Yellow zone, according to TradeSmith. NAMSW has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMSW CIK1936258 Webwww.newamsterdampharma.com Phone31 35 206 2971FaxN/AEmployees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$25.94 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NAMSW) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.